Jump to content
Powered by BIOPRO BW
  • BIOPRO BW
  • Healthcare industry
  • Project pages
    • MDR & IVDR
    • Innovation & Startups
Healthcare industry Logo

Main navigation

  • Start page Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close Close
  • Databases

    Databases

    Close Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Press release - 04/02/2026

    A double-edged sword: Chronic cellular stress promotes liver cancer - but at the same time renders tumors vulnerable to immunotherapy

    A key molecular mechanism drives the growth of liver cell cancer while simultaneously suppressing the body's immune response to the tumor. This has now been published in the journal Nature by a team led by researchers from the DKFZ, the UKT, and the Sanford Burnham Prebys Medical Discovery Institute. However, the results also show that this very mechanism could help identify patients who respond particularly well to immunotherapy in the…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/double-edged-sword-chronic-cellular-stress-promotes-liver-cancer-same-time-renders-tumors-vulnerable-immunotherapy
  • Rewriting the transcript to heal diseases - 29/01/2026 A colourful mRNA to which an arginyl tRNA docks. Both nucleic acid sequences are modified at one point.

    Therapy involving the umlauts of the genetic alphabet

    tRNAs are essential components of the protein synthesis machinery that also act as molecular switches in gene regulation and consequently in disease processes such as cancer. The Heidelberg-based start-up Umlaut.bio is developing novel therapeutics that specifically target tRNAs to intervene at the molecular origin of disease.

    https://www.gesundheitsindustrie-bw.de/en/article/news/therapy-involving-umlauts-genetic-alphabet
  • Press release - 22/01/2026

    Knowledge Connector: better clinical decisions in molecular precision oncology

    Researchers at the National Center for Tumor Diseases (NCT) Heidelberg and the German Cancer Research Center (DKFZ) have developed a digital tool that significantly accelerates and improves clinical decisions in molecular precision oncology. The Knowledge Connector enables the structured and standardized evaluation of very extensive molecular tumor profiles and makes them available for personalized therapy decisions faster than before.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/knowledge-connector-better-clinical-decisions-molecular-precision-oncology
  • Press release - 17/12/2025

    Improving cancer therapy with artificial organs DFG funds research training group "Org-BOOST" with around nine million euros

    Recreating tumour tissue in the laboratory as realistically as possible and developing new approaches for personalised cancer medicine: A total of 20 doctoral students in the life sciences and ten Medicine students will be researching this in the new "Organoid-Based mOdelling of Solid Tumours" research training group. They want to gain a better understanding of cancer and better predict the course of the disease and the effect of…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/improving-cancer-therapy-artificial-organs-dfg-funds-research-training-group-org-boost-around-nine-million-euros
  • Press release - 17/12/2025

    mRNA rejuvenates aging immune system - the liver as a fountain of youth

    Can the weakened immune systems of older individuals be rejuvenated? Researchers from the DKFZ, HI-STEM*, and the Broad Institute have demonstrated that this is possible with an innovative approach. In a study, the team showed that mRNA technology can be used to transform the liver in mice into a temporary source of important immune regulatory factors that are naturally lost during aging.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/mrna-rejuvenates-aging-immune-system-liver-fountain-youth
  • Press release - 16/12/2025

    New measures to make EU health sector more innovative, competitive and resilient

    The European Commission has today proposed an ambitious package of measures to improve the health of EU citizens, while ensuring the long-term resilience and competitiveness of the health sector.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-measures-make-eu-health-sector-more-innovative-competitive-and-resilient
  • Press release - 08/12/2025

    New mutation catalog facilitates personalized cancer therapy

    When gene mutations are found in the tumor of cancer patients, it is often unclear whether they promote tumor growth or whether a targeted therapy could be effective. A research team led by the Medical Center - University of Freiburg has now compiled a catalog in which over 11,000 gene variants of a central gene family were examined and evaluated for their role in tumor growth.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-mutation-catalog-facilitates-personalized-cancer-therapy
  • Press release - 25/11/2025

    CELLnROLL receives funding from EXIST Research Transfer

    CELLnROLL is a spin-off from the Max Planck Institute for Intelligent Systems. The newly founded company develops a high-precision microrobotic-based cell sorting system to help clinicians make fast, affordable, and informed decisions for cancer diagnostics. Now, the project has received €865,000 in funding through the EXIST Transfer of Research program, a funding program initiated by the German Federal Ministry for Economic Affairs and Energy.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/cellnroll-receives-funding-exist-research-transfer
  • Press release - 24/11/2025

    Shield against metastases and genetically protected CAR-T cells: Double honor for Mirco Julian Friedrich

    Physician and cancer researcher Mirco Julian Friedrich from the German Cancer Research Center (DKFZ), the stem cell research institute HI-STEM*, and Heidelberg University Hospital (UKHD) has received two awards for two independent research projects: his novel approach to preventing liver metastases and his research on T cells, which he modifies to better protect them from attacks by natural killer cells.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/shield-against-metastases-and-genetically-protected-car-t-cells-double-honor-mirco-julian-friedrich
  • Press release - 17/11/2025

    How painkillers can contribute to anemia in cancer patients

    Researchers from the German Cancer Research Center and the University of Freiburg show how certain painkillers influence the iron metabolism of liver cancer cells and can thus contribute to iron deficiency and anemia in cancer patients.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-painkillers-can-contribute-anemia-cancer-patients
  • Press release - 07/11/2025

    Overcoming Tumor Resistance to Immunotherapy: The European Research Council awards international project led by Heidelberg Medical Faculty

    In the PRECISION-ImmunoRad project, a multidisciplinary team of scientists from Heidelberg, USA, and Cyprus will unite their expertise to develop novel curative therapeutic strategies for currently hard-to-treat cancers. These strategies will integrate high-precision ion beam therapy with genetically engineered immune cells therapies (CAR-T cells), personalized cancer vaccines, and the targeted reprogramming of the tumor immune microenvironment.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/overcoming-tumor-resistance-immunotherapy-european-research-council-awards-international-project-led-heidelberg-medical-faculty
  • Artificial intelligence: opportunities for healthcare - 06/11/2025 Graphic showing various options for integrating GenAI into a company. These are via SiaS tokens, in a private cloud and with proprietary hardware. They are compared in terms of initial costs, running costs, data security and dependency.

    More than just deskwork: opportunities and obstacles for generative AI in healthcare

    Generative artificial intelligence (GenAI) has enormous potential in healthcare, ranging from automating time-consuming deskwork to supporting diagnoses. It is not just for the big players; there are also cost-effective ways for smaller companies and institutions to utilize GenAI.

    https://www.gesundheitsindustrie-bw.de/en/article/news/more-just-deskwork-opportunities-and-obstacles-generative-ai-healthcare
  • Press release - 04/11/2025

    Brain Tumor Charity supports immunotherapy for childhood brain tumors with 1.5 million pounds sterling

    Ependymomas, brain tumors that occur particularly in young children, are especially difficult to treat and more than half of the children affected have an increased risk of relapse. As part of an international consortium, the KiTZ, the DKFZ, the MFHD and UKHD have received a grant of 1.5 million pounds sterling (GBP) from the British organization The Brain Tumor Charity to develop a new type of immunotherapy for ependymoma.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/brain-tumor-charity-supports-immunotherapy-childhood-brain-tumors-15-million-pounds-sterling
  • Press release - 29/10/2025

    Replacing, reducing and refining animal testing Official launch of integrative 3R Centre at Ulm University

    Developing replacement methods for animal testing is the main goal of the 3R network. One of three new 3R centres in Baden-Württemberg was launched at Ulm University at the beginning of the year and has now officially started work with a kick-off event. The abbreviation 3R stands for "Replace, Reduce, Refine", i.e. replace and reduce animal testing and improve the conditions for unavoidable animal experiments.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/replacing-reducing-and-refining-animal-testing-official-launch-integrative-3r-centre-ulm-university
  • Press release - 28/10/2025

    AI solutions from the DKFZ set new standards in medical image processing

    Researchers at the German Cancer Research Center (DKFZ) have achieved outstanding success at this year's world-leading forum for medical image processing and computer-assisted intervention. Two DKFZ departments competed in eight international AI competitions – and won seven of them. The successes cover key areas of oncology – from early detection and diagnosis to therapy support and follow-up care.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/ai-solutions-dkfz-set-new-standards-medical-image-processing
  • Press release - 27/10/2025

    OnkoAktiv receives Cancer Innovation Award 2025

    The nationwide OnkoAktiv network, founded at the National Center for Tumor Diseases (NCT) in Heidelberg, has been awarded the Baden-Württemberg Cancer Innovation Prize 2025. The prize recognizes OnkoAktiv for its pioneering role and groundbreaking contribution to the integration of exercise into oncological care.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/onkoaktiv-receives-cancer-innovation-award-2025
  • Press release - 16/10/2025

    Sleep as the key to understanding ME/CFS

    The Federal Ministry of Research, Technology and Space (BMFTR) is supporting the “Sleep-Neuro-Path” research network with around 1.6 million euros. Coordinated by the Central Institute of Mental Health (CIMH) in Mannheim, a team of scientists is investigating the role of sleep-related biomarkers in the development of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/sleep-key-understanding-mecfs
  • Press release - 15/10/2025

    NGS-based diagnostics for identifying sepsis pathogens wins EARTO Innovation Award

    A method developed at the Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB enables bacterial, viral, fungal, or parasitic pathogens in sepsis patients to be identified much faster than before and with the highest precision. The approach is based on high-throughput sequencing of cell-free DNA circulating in the blood and was honored with the EARTO Innovation Award in the "Impact Delivered" category on October 14,…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/ngs-based-diagnostics-identifying-sepsis-pathogens-wins-earto-innovation-award
  • Press release - 10/10/2025

    Acidic tumor environment promotes survival and growth of cancer cells

    Tumors are not a comfortable place to live: oxygen deficiency, nutrient scarcity, and the accumulation of sometimes harmful metabolic products constantly stress cancer cells. A research team from the DKFZ and the IMP in Vienna has now discovered that the acidic pH value in tumor tissue is a decisive factor in how pancreatic cancer cells adapt their energy metabolism in order to survive under these adverse conditions.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/acidic-tumor-environment-promotes-survival-and-growth-cancer-cells
  • Press release - 09/10/2025

    Another step towards a cure Vitamin A transporter reactivates latent HIV

    Human immunodeficiency viruses (HIV) are insidious. They can evade the immune defence and antiviral drugs by becoming "latent". In this state, they are largely invisible and unassailable. As long as these dormant viruses persist, there is no cure for HIV/AIDS. However, researchers at Ulm University Hospital have discovered a new way to reactivate latent HI viruses.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/another-step-towards-cure-vitamin-transporter-reactivates-latent-hiv
  • Press release - 06/10/2025

    3D imaging points to possible cause of sudden cardiac death

    An imaging technique developed by Freiburg researchers provides insights into cardiac arrhythmias that can cause sudden cardiac death in animal models. The changes discovered could explain why even seemingly healthy people are sometimes affected.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/3d-imaging-points-possible-cause-sudden-cardiac-death
  • Press release - 29/09/2025

    Actin scaffold in cell nucleus explains survival of cancer cells

    Researchers from the Cluster of Excellence CIBSS have demonstrated that an actin scaffold stabilizes the cell nucleus upon mechanical stress. This protective mechanism helps cancer cells to avoid dying during their migration in the body. In the long term, targeted interventions in this mechanism could help to prevent metastases.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/actin-scaffold-cell-nucleus-explains-survival-cancer-cells
  • Press release - 23/09/2025

    Mutation in non-coding DNA worsens leukaemia prognosis Ulm study uncovers previously unknown disease-promoting mechanism

    Why is blood cancer particularly aggressive in some patients? Researchers at Ulm University Hospital have characterised a mutation in the so-called NOTCH1 gene that significantly influences the prognosis of chronic lymphocytic leukaemia (CLL). Remarkably, this mutation is located in the non-coding region of the gene – an area of DNA long considered less relevant for disease mechanisms.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/mutation-non-coding-dna-worsens-leukaemia-prognosis-ulm-study-uncovers-previously-unknown-disease-promoting-mechanism
  • Press release - 23/09/2025

    Not all ALK fusions act the same: Variants influence treatment success in lung cancer

    About five percent of lung adenocarcinomas, one of the most common forms of lung cancer, are driven by a faulty fusion of two genes, EML4 and ALK. This fusion results in different variants, and until now, clinicians have treated all patients with these fusions the same way. However, new research led by scientists from the German Cancer Research Center (DKFZ) and Stanford University shows that not all fusion variants behave alike.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/not-all-alk-fusions-act-same-variants-influence-treatment-success-lung-cancer
  • Press release - 16/09/2025

    New CRISPR method leads to a better understanding of cell functions

    The 2020 Nobel Prize in Chemistry was awarded for the development of CRISPR/Cas9, a method also known as “gene scissors”, which enables researchers to better understand how human cells function and stay healthy. Researchers at the University of Stuttgart have further developed CRISPR for this purpose. They present their CRISPRgenee method in Cell Reports Methods.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-crispr-method-leads-better-understanding-cell-functions
  • Press release - 15/09/2025

    How HIV enters the genome – Researchers identify previously unknown mechanism

    Researchers at Heidelberg Uni Hospital have decoded a previously unknown mechanism by which HIV-1 selects its integration targets in the human genome. A research team identified RNA:DNA hybrids as molecular signposts for the virus. These findings reveal a vulnerability in the life cycle of HIV and provide therapeutic approaches for specifically controlling HIV reservoirs in the body. This has been one of the obstacles to curative HIV therapies.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-hiv-enters-genome-researchers-identify-previously-unknown-mechanism
  • Press release - 12/09/2025

    In bad company: Immune cells in the tumor environment determine the success of therapy for childhood brain tumors

    The cellular environment of a tumor can either support or sabotage recovery. The most comprehensive study to date on the tumor microenvironment in low-grade gliomas, conducted by KiTZ, Jena University Hospital, the DKFZ, and Heidelberg University Hospital, shows what a supportive or obstructive “neighborhood” looks like in childhood brain tumors. The study also provides clues as to how tumor communication might be blocked.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/bad-company-immune-cells-tumor-environment-determine-success-therapy-childhood-brain-tumors
  • Press release - 09/09/2025

    Molecular Biomimetics: The Cell Nucleus as a Model for DNA-based Computer Chips

    In the human body, stem cells process genetic information in an exceptionally reliable and very fast manner. To do this, they access certain sections of the DNA in the cell nucleus. Researchers at KIT have investigated how the DNA-based information processing system works. Their results show that this process is comparable to processes in modern computers and could therefore serve as a model for new types of DNA-based computer chips.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/molecular-biomimetics-cell-nucleus-model-dna-based-computer-chips
  • Press release - 04/09/2025

    Rare bone tumors: Tailor-made mini-proteins switch off tumor drivers

    Chordomas are rare bone tumors for which there are no effective drugs. A research team from the DKFZ and the NCT Heidelberg has now developed a promising approach: Tailor-made mini-proteins specifically block the driver of tumor development. In the result, slowing the growth of chordoma cells in the laboratory and in a mouse model, while also revealing further molecular vulnerabilities of the tumor that could be addressed with approved drugs.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/rare-bone-tumors-tailor-made-mini-proteins-switch-tumor-drivers-1
  • Press release - 03/09/2025

    Therapeutic vaccination against HPV-related tumors: Nanoparticles make the difference

    Researchers from the German Cancer Research Center (DKFZ) have collaborated with the SILVACX project group at Heidelberg University to develop a therapeutic vaccination concept that can mobilize the immune system to target cancer cells. The team showed that virus peptides coupled to silica nanoparticles can elicit effective T-cell responses against HPV-related tumors.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/therapeutic-vaccination-against-hpv-related-tumors-nanoparticles-make-difference
  • Press release - 28/08/2025

    Inhibition of cell division induces immunoreactive peptides in cancer cells

    A team of scientists from the German Cancer Research Center (DKFZ) and the Netherlands Cancer Institute has discovered a previously unknown vulnerability in cancer cells: When cell division is blocked with chemotherapeutic agents such as Taxol, cancer cells produce small immunogenic peptides that could open up new avenues for immune-based cancer therapies.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/inhibition-cell-division-induces-immunoreactive-peptides-cancer-cells
  • Press release - 21/08/2025

    Nanodroplets Could Speed Up the Search for New Medicine

    Until now, the early phase of drug discovery for the development of new therapeutics has been cost- and time-intensive. Researchers at KIT have developed a platform on which extremely miniaturized nanodroplets with a volume of 200 nanoliters per droplet and containing 300 cells per test can be arranged. This platform enables the researchers to synthesize and test thousands of therapeutic agents on the same chip, saving time and resources.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/nanodroplets-could-speed-search-new-medicine
  • Press release - 14/08/2025

    Freezing brain tumor cells in a dormant state

    Every brain tumor is made up of cells in successive stages of activation. Researchers have now analyzed the individual structure of these activation pyramids in malignant brain tumors. In doing so, they discovered a signaling protein that slows down the transition from a dormant to an activated state by epigenetically reprogramming the cells. The hope is that this will permanently freeze cancer cells in a dormant state and thus halt tumor growth.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/freezing-brain-tumor-cells-dormant-state
  • Press release - 12/08/2025

    Biomarkers for Brain Insulin Resistance Discovered in the Blood

    If the brain no longer responds properly to insulin (insulin resistance), this can lead to overweight, diabetes, and Alzheimer's disease. Researchers at the DZD in Potsdam and Tübingen have discovered small chemical modifications to genetic material (epigenetic changes*) in the blood that indicate how well the brain responds to insulin. These markers could help to detect insulin resistance in the brain – by means of a simple blood test.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/biomarkers-brain-insulin-resistance-discovered-blood
  • Press release - 05/08/2025

    Playing Dominos: how an artificial protein emerges from fitting together individual components

    The targeted engineering of artificial proteins with unique properties – that is possible with the assistance of a novel method developed by a research team of Heidelberg University. It centers around a new AI model. This allows for forecasting how two proteins have to be fitted together at the molecular level from individual parts – subunits – in order to engineer a functional, adjustable new protein.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/playing-dominos-how-artificial-protein-emerges-fitting-together-individual-components
  • Press release - 04/08/2025

    FOXP1 syndrome: Potential therapeutic approach discovered for rare language development disorder

    FOXP1 syndrome is a congenital disorder in which the brain development of affected children is severely impaired due to a genetic variant. A research team from the Medical Faculty Heidelberg at Heidelberg University has now demonstrated in mice, that the inhibition of a specific enzyme in the brain can improve abnormal behavior and immune cell dysfunction in the brain. The results have been published in the journal Advanced Science.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/foxp1-syndrome-potential-therapeutic-approach-discovered-rare-language-development-disorder
  • Breath test replaces invasive diagnostics - 30/07/2025 Der Sensor auf einer Handfläche, der gerade einmal ein Drittel der des Handtellers bedeckt.

    Novel smartphone sensor offers innovative breath test to detect Helicobacter infection

    The stomach bacterium Helicobacter pylori is widespread and, if left undetected, can impact our well-being and also lead to serious health conditions. While effective treatments exist, a reliable diagnosis is essential. To address this, researchers have developed an affordable breath test that uses a mini-sensor to detect the presence of the bacterium. They are currently working on a smartphone-compatible version for self-testing.

    https://www.gesundheitsindustrie-bw.de/en/article/news/novel-smartphone-sensor-offers-innovative-breath-test-detect-helicobacter-infection
  • Press release - 29/07/2025

    New method to design custom protein binder

    Designing protein binders from scratch has long been a daunting challenge within the field of computational biology. Researchers have now developed an innovative, training-free pipeline that uses the fundamental principle of shape complementarity to design site-specific protein binders, which are then optimised to fit precisely onto chosen target sites. The researchers tested this on proteins linked to cancer.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-method-design-custom-protein-binder
  • Press release - 24/07/2025

    The origin of evil: stem cell-like cells are the reason for relapses of blood cancer in children and adolescents

    Stem cell-like leukemia cells are responsible for relapses in children and adolescents with a certain type of blood cancer, T-ALL. Researchers at the Hopp Children's Cancer Center Heidelberg (KiTZ), the Molecular Medicine Partnership Unit and the German Cancer Research Center were able to show this in a study. The results could help to overcome resistance in this form of blood cancer and prevent relapses.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/origin-evil-stem-cell-cells-are-reason-relapses-blood-cancer-children-and-adolescents
  • Press release - 24/07/2025

    What makes cells migrate – and what can stop them

    Konstanz researchers identify an enzyme that plays a role in the migration of cells in our body - not only during normal tissue formation and wound healing, but also when tumor cells metastasize. This makes the enzyme an interesting candidate for potential future therapeutic approaches.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/what-makes-cells-migrate-and-what-can-stop-them
  • Press release - 22/07/2025

    Colorectal cancer in type 2 diabetes: An insightful look into the microenvironment of tumors

    Diabetics have a higher risk of colorectal cancer and often a poorer prognosis after developing the disease. The biological mechanisms behind this association were largely unknown. A research team at the German Cancer Research Center (DKFZ) has now discovered that tumors with a low number of immune cells appear to be particularly susceptible to the harmful effects of diabetes.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/colorectal-cancer-type-2-diabetes-insightful-look-microenvironment-tumors
  • Press release - 21/07/2025

    Cancer Cachexia: Liver Identified as Driver of Body Wasting

    Many people with cancer experience dramatic loss of muscle and fat tissue. In many cases, even the heart muscle is affected. This wasting syndrome, affects around half of all cancer patients. Researchers from Helmholtz Munich, in collaboration with Heidelberg University Hospital, the Technical University of Munich, and the German Center for Diabetes Research, have now identified a previously overlooked driver of cachexia: the liver.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/cancer-cachexia-liver-identified-driver-body-wasting
  • Press release - 15/07/2025

    Mapping the metabolism of blood stem cells

    Researchers from the Max Planck Institute of Immunobiology and Epigenetics in Freiburg and ETH Zürich have created the first integrated map detailing the metabolic and molecular changes in human blood stem cells as they age, specialize, or turn cancerous. Their innovative research, made possible by highly sensitive low-input techniques, identifies the nutrient choline, as a key player in preserving youthful stem cell traits.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/mapping-metabolism-blood-stem-cells
  • Press release - 15/07/2025

    ERC funding for research into improved cancer immunotherapies

    With its Proof of Concept grants, the European Research Council (ERC) supports scientists in further developing the economic potential of their research results. Two scientists from the German Cancer Research Center (DKFZ) have now received this coveted funding for the second time.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/erc-funding-research-improved-cancer-immunotherapies
  • Press release - 11/07/2025

    Cellular stress response – researchers discover potential therapeutic target for heart failure

    Researchers at the German Centre for Cardiovascular Research (DZHK) have identified a key molecule involved in a form of heart failure that has so far been difficult to treat.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/cellular-stress-response-researchers-discover-potential-therapeutic-target-heart-failure
  • Press release - 08/07/2025

    Five million euros for research into early cancer detection

    Investing in a healthier future: The HORNBACH Group is supporting the new National Cancer Prevention Center in Heidelberg with a donation of five million euros. In the future, a new laboratory will conduct research into more effective early detection and screening methods.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/five-million-euros-research-early-cancer-detection
  • Press release - 04/07/2025

    Breakthrough in Artificial Blood Production

    Scientists have been working on the artificial production of blood for several decades. Making a new discovery, researchers from the Institute for Cellular Biology and Immunology Thurgau at the University of Konstanz, in collaboration with Queen Mary University of London, have come an important step closer to this goal.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/breakthrough-artificial-blood-production
  • Press release - 03/07/2025

    Focus on Muscle Metabolism: Sex Differences in Sport and Obesity

    The skeletal muscles of men and women process glucose and fats in different ways. A study provides the first comprehensive molecular analysis of these differences. The results possibly give an explanation why metabolic diseases such as diabetes manifest differently in women and men – and why they respond differently to physical activity.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/focus-muscle-metabolism-sex-differences-sport-and-obesity
  • Computer tool opens up new ways to address antibiotic resistance - 02/07/2025 Graphic and symbolic explanation of how PhARIS works. Phages are analysed and thus identified.

    PhARIS identifies effective phages against multi-resistant bacteria

    Bacteriophages - viruses that specifically attack and destroy bacteria - are emerging as promising alternatives to antibiotics in the fight against drug-resistant infections. To speed this effort, researchers have created PhARIS, a computational tool that mines genomic data to pinpoint phages that are effective against S. aureus. By rapidly matching phage and pathogen, PhARIS can accelerate the development of targeted phage therapies.

    https://www.gesundheitsindustrie-bw.de/en/article/news/pharis-identifies-effective-phages-against-multi-resistant-bacteria
  • Press release - 16/06/2025

    Novel laboratory models pave the way for targeted therapies for childhood sarcomas

    Sarcomas in soft tissue usually occur in young people and are difficult to treat. Due to a lack of laboratory models, the causes of their development are poorly understood. A team of researchers has now succeeded in creating mouse models with a functioning immune system that replicate sarcoma types that remain unstudied. The method opens up new avenues for the targeted development of immunotherapies for children and adolescents with sarcomas.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/novel-laboratory-models-pave-way-targeted-therapies-childhood-sarcomas

Page 1 / 6

sb_search.block.search_result.other.pages

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • MDR & IVDR
    • Innovation & Startups
  • Portals
    • BIOPRO BW
    • Healthcare industry
  • To top

stay informed

Newsletter abonnieren

Social Media

  • Xing Xing
  • Twitter visit Twitter
  • LinkedIn visit LinkedIn
  • Rss visit RSS
  • Privacy statement
  • Accessability Declaration
  • Legal notice
  • Sitemap
  • Contact
© 2026
Website address: https://www.gesundheitsindustrie-bw.de/en/search